New S ‐substituted‐3‐phenyltetrahydrobenzo[4,5]thieno[2,3‐ d ]pyrimidin‐4(3 H )‐one scaffold with promising anticancer activity profile through the regulation and inhibition of mutated B‐RAF signaling pathway
Drug Development Research · 2024-11 · 85 (7)
DOI: 10.1002/ddr.70007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, online erschienen am 18.10.2024. Verfasst von Safaa E Seif und 4 weiteren Autor:innen. Beteiligte Einrichtung: National Organization for Drug Control and Research, Cairo, Egypt. Hauptthemen laut MEDLINE: Antineoplastic Agents, Proto-Oncogene Proteins B-raf, Pyrimidines, Signal Transduction. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 77 Literaturangaben.
Abstract (Originalsprache)
Novel 3‐phenyltetrahydrobenzo[4,5]thieno[2,3‐ d ]pyrimidine derivatives were synthesized and screened for their antiproliferative activity against a panel of 60 cancer cell lines. Derivatives 5b , 5f , and 9c showed significant antitumor activity at a single dose with mean growth inhibition of 55.62%, 55.79%, and 71.40%, respectively. These compounds were further investigated against HCT‐116, colon cancer cell line, and FHC, normal colon cell line. Compound 9c showed the highest activity with IC 50 = 0.904 ± 0.03 µM and SI = 20.42 excelling doxorubicin which scored IC 50 = 2.556 ± 0.09 µM and SI = 6.19. Compound 9c was also the most potent against B‐RAF WT and mutated B‐RAF V600E with IC 50 = 0.145 ± 0.005 and 0.042 ± 0.002 µM, respectively in comparison with vemurafenib with IC 50 = 0.229 ± 0.008 and 0.038 ± 0.001 µM, respectively. The cell cycle analysis showed that 9c increased the cell population and induced an arrest in the cell cycle of HCT‐116 cancer cells at the G0‐G1 stage with 1.23‐fold. Apoptosis evaluation showed that compound 9c displayed an 18.18‐fold elevation in total apoptosis of HCT‐116 cancer cells in comparison to the control. Compound 9c increased the content of caspase‐3 by 3.52‐fold versus the control. A molecular modeling study determined the binding profile and interaction of 9c with the B‐RAF active site.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Organization for Drug Control and Research, Cairo, Egypt.
- Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, 11562, Egypt.
- Department of Microbiology and Immunology, National Research Centre, Dokki, Giza, 12622, Egypt.
ORCID-Profile: Rasha A Hassan, Zeinab Mahmoud
Zitieren
APA
Seif, S. E., Wardakhan, W. W., Hassan, R. A., Abdou, A. M., & Mahmoud, Z. (2024). New S ‐substituted‐3‐phenyltetrahydrobenzo[4,5]thieno[2,3‐ d ]pyrimidin‐4(3 H )‐one scaffold with promising anticancer activity profile through the regulation and inhibition of mutated B‐RAF signaling pathway. Drug Development Research, 85(7). https://doi.org/10.1002/ddr.70007
Vancouver
Seif SE, Wardakhan WW, Hassan RA, Abdou AM, Mahmoud Z. New S ‐substituted‐3‐phenyltetrahydrobenzo[4,5]thieno[2,3‐ d ]pyrimidin‐4(3 H )‐one scaffold with promising anticancer activity profile through the regulation and inhibition of mutated B‐RAF signaling pathway. Drug Development Research. 2024;85(7). doi:10.1002/ddr.70007
BibTeX
@article{Seif2024,
author = {Seif, Safaa E and Wardakhan, Wagnat W and Hassan, Rasha A and Abdou, Amr M and Mahmoud, Zeinab},
title = {New S ‐substituted‐3‐phenyltetrahydrobenzo[4,5]thieno[2,3‐ d ]pyrimidin‐4(3 H )‐one scaffold with promising anticancer activity profile through the regulation and inhibition of mutated B‐RAF signaling pathway},
journal = {Drug Development Research},
year = {2024},
volume = {85},
number = {7},
doi = {10.1002/ddr.70007}
}
EUVIMED